Search alternatives:
significantly larger » significantly lower (Expand Search), significantly smaller (Expand Search), significantly higher (Expand Search)
larger decrease » marked decrease (Expand Search)
small decrease » small increased (Expand Search)
point decrease » point increase (Expand Search)
significantly larger » significantly lower (Expand Search), significantly smaller (Expand Search), significantly higher (Expand Search)
larger decrease » marked decrease (Expand Search)
small decrease » small increased (Expand Search)
point decrease » point increase (Expand Search)
-
161
-
162
Average % peptides counts for different classes of proteins at different germination time points and significant p-value indicated as compared to soaked sample (*p< 0.05, **p<0.01, ***p<0.001) for brown non-trypsinised with shades of green showing increase and red showing decrease with respect to soaked.
Published 2024“…<p>Average % peptides counts for different classes of proteins at different germination time points and significant p-value indicated as compared to soaked sample (*p< 0.05, **p<0.01, ***p<0.001) for brown non-trypsinised with shades of green showing increase and red showing decrease with respect to soaked.…”
-
163
Average of % peptides counts for different classes of proteins at different germination time points and significant p-value indicated as compared to soaked sample (*p< 0.05, **p<0.01, ***p<0.001) for garbanzo non-trypsinised with shades of green showing increase and red showing decrease with respect to soaked.
Published 2024“…<p>Average of % peptides counts for different classes of proteins at different germination time points and significant p-value indicated as compared to soaked sample (*p< 0.05, **p<0.01, ***p<0.001) for garbanzo non-trypsinised with shades of green showing increase and red showing decrease with respect to soaked.…”
-
164
-
165
-
166
-
167
Summary of post-treatment disease course measures from MDMA-AT publications.
Published 2025Subjects: -
168
-
169
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
Published 2025Subjects: -
170
-
171
-
172
-
173
Summary of post-treatment disease course measures from off-label medications clinical trials.
Published 2025Subjects: -
174
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
Published 2025Subjects: -
175
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
Published 2025Subjects: -
176
Summary of post-treatment disease course measures from clinical trials with psychotherapies.
Published 2025Subjects: -
177
-
178
-
179
Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.
Published 2025Subjects: -
180